Healthline: Rates of IBD including Crohn’s Disease are three times higher than realized
UC digestive diseases expert discusses treatment options
A journalist for Healthline spoke with Loren Brook, MD, an assistant professor in the UC Department of Internal Medicine, about possible treatments for inflammatory bowel disease (IBD). In 2015, more than 3 million U.S. adults reported a diagnosis of IBD, an ongoing inflammation of all or part of the digestive tract, and includes two conditions, Crohn’s Disease and ulcerative colitis.
Brook, also a UC Health physician, explained the disease is usually lifelong but can be managed with relatively minor anti-inflammatory drugs such as oral mesalamine to immune-suppressing medications such as Remicade or steroids.
Related Stories
UC studies: Silent mutations, tumor microenvironment may be therapeutic targets
April 17, 2026
University of Cincinnati Cancer Center researchers will present abstracts at the American Association for Cancer Research Annual Meeting 2026 April 17 to 22 in San Diego.
UC experts present neurology research at national conference
April 17, 2026
University of Cincinnati researchers will present abstracts at the 2026 American Academy of Neurology Annual Meeting April 18 to 22 in Chicago.
AI advances in the liver disease field
April 15, 2026
MASH represents the advanced inflammatory form of metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as nonalcoholic fatty liver disease), where fat accumulation in the liver triggers fibrosis and progressive liver injury. According to a recent MedCentral article, more AI-based clinical assessment tools in MASH are needed.